- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Best Practices for Employers to Maximize Uptake of Biosimilars
Panelists discuss how employers optimize biosimilar uptake through strategic formulary design, financial incentives, and provider education, enabling health care systems to achieve substantial cost savings while maintaining high-quality patient care.
EP: 1.Clinical Value of Biosimilars and the Role of Interchangeability
EP: 2.The Economic Impact of Biosimilars
EP: 3.Best Practices for Employers to Maximize Uptake of Biosimilars
EP: 4.The Role of Private Label Agreements in Enhancing Access to Biosimilars
EP: 5.Key Structural and Operational Considerations for Biosimilar Adoption
EP: 6.Positioning Biosimilars in Clinical Practice
EP: 7.Assessing Patient Confidence With Biosimilars
EP: 8.The Role of Different Stakeholders in Optimizing the Uptake of Biosimilars
Video content above is prompted by the following:
- What are best practices for employers working with pharmacy benefit managers and health plans to ensure maximal uptake and cost savings of biosimilars?
- Please share how you were able to achieve this in practice.
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
Solving the Transition Conundrum as More Children With Muscular Dystrophy Live to Adulthood
March 17th 2025Learning from examples like congenital heart disease and cystic fibrosis can help health systems and clinicians prepare to care for an influx of patients with neuromuscular diseases as they reach adulthood thanks to transformative therapy advances.
Read More
